Tadalafil Tablet, Film Coated
Product Images NDC 16729-370

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 16729-370). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tablets, Usp 2.5 mg (Carton)

Packaging label for Tadalafil Tablets USP 2.5 mg from Accord Healthcare Inc., containing 30 tablets in 2 blister strips of 15 tablets each. The label highlights the 2.5 mg strength with instructions for once daily use, warnings, NDC number 16729-369-97, and manufacturer information. The label includes dosage notes and barcode.*

FDA Label Image

Tadalafil Tablets, Usp 5 mg (Carton)

Packaging label for Tadalafil Tablets USP, 5 mg oral film-coated tablets. The label indicates a package containing 30 tablets divided into 2 blister strips of 15 tablets each. The product is manufactured for Accord Healthcare Inc. The label includes warnings and usage instructions emphasizing once daily use and dosage guidelines.*

FDA Label Image

Figure (Tadalafil Figure1)

Four line graphs depicting the difference in blood pressure measurements (Tadalafil minus placebo) over time (0 to 96 hours). The graphs show standing systolic and diastolic blood pressure on the top row and supine systolic and diastolic blood pressure on the bottom row, with values on the y-axis as difference in mmHg and x-axis as time in hours.*

FDA Label Image

Figure (Tadalafil Figure2)

This figure presents two line graphs depicting changes in systolic blood pressure (standing and supine) over a 24-hour period post-dose. The graphs compare Tadalafil 20 mg combined with doxazosin 8 mg (solid lines) against placebo with doxazosin 8 mg (dotted lines), showing blood pressure measurements on the y-axis and time in hours after dosing on the x-axis.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph showing systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo, combined with 8 mg qd doxazosin at 08:00. Four data series compare 20 mg tadalafil at 08:00 and 20:00 versus placebo, illustrating blood pressure trends over time.*

FDA Label Image

Figure (Tadalafil Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) following different dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg doses after 5 days of administration. Data points include error bars indicating variability.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

Line graph depicting the change from baseline in IPSS Total Score over 12 weeks of treatment. It compares tadalafil 5 mg and placebo groups, showing greater reduction in score for tadalafil over time. The x-axis shows treatment duration in weeks, and the y-axis shows change from baseline. A statistical significance marker is present.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph depicting the change from baseline in IPSS Total Score over a 12-week duration of treatment comparing tadalafil 5 mg and placebo. The vertical axis shows the change in score, and the horizontal axis represents weeks of treatment. The tadalafil group shows a greater decrease in score than placebo, with significant differences marked (p<0.01).*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph showing least-squares mean change from baseline over weeks of therapy (0, 4, 12, and 26) comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The graph plots two data series with Tadalafil/Finasteride represented by diamonds and Placebo/Finasteride by circles, indicating greater improvement with Tadalafil/Finasteride at each time point. Statistical significance is noted with p-values.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph illustrating the change from baseline in IPSS total score over a 12-week treatment duration. The graph compares two groups: tadalafil 5 mg and placebo. The tadalafil group shows a greater reduction in IPSS score compared to placebo, with statistical significance indicated at 12 weeks (p<0.01). The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in IPSS total score.*

FDA Label Image

Tadalafil Label 10mg

Label for Tadalafil Tablets, USP 10 mg film-coated tablets by Accord Healthcare Inc. The label includes storage instructions, a dosage warning, and indicates the package contains 30 tablets. It also shows the NDC 16729-371-10 and barcode.*

FDA Label Image

Tadalafil Tablets, Usp 20 mg (Label)

Label for Tadalafil Tablets USP 20 mg by Accord Healthcare Inc. The label includes dosing instructions, storage conditions, warnings, and manufacturer details. It indicates a 30-tablet package with prescription-only status and advises against splitting tablets. The label also features barcodes and batch information areas.*

FDA Label Image

Tadalafil Tablets, Usp 2.5 mg (Label)

Tadalafil 2.5 mg film-coated tablets label showing the drug name, strength, dosage form, and manufacturer information. The label includes storage instructions, warnings, and dosage advisory. It states the package contains 30 tablets and is labeled by Accord Healthcare Inc. The label features barcodes and information about manufacturing by Intas Pharmaceuticals Limited in India.*

FDA Label Image

Tadalafil Tablets, Usp 5 mg (Label)

Tadalafil Tablets USP 5 mg film-coated oral tablets, prescription only, in a package of 30 tablets. The label includes storage instructions to keep at controlled room temperature, a warning to keep out of reach of children, and directions that tablets should not be split. The product is manufactured by Accord Healthcare Inc. and Intas Pharmaceuticals Limited, India. The label shows NDC 16729-370-10 and includes barcodes.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure diagram of tadalafil, showing its molecular connectivity including fused ring systems and characteristic functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.